<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01278303</url>
  </required_header>
  <id_info>
    <org_study_id>G060057a</org_study_id>
    <secondary_id>RFD003898A</secondary_id>
    <nct_id>NCT01278303</nct_id>
  </id_info>
  <brief_title>Covered CP Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta</brief_title>
  <acronym>COASTII</acronym>
  <official_title>Covered Cheatham Platinum Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Richard E. Ringel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coarctation of the aorta (CoA) is a congenital abnormality producing obstruction to blood&#xD;
      flow through the aorta. Coarctation can occur in isolation, in association with bicuspid&#xD;
      aortic valve or with major cardiac malformations. CoA accounts for 5-8% of the 8/1000&#xD;
      (4-6/10,000) children born with congenital heart disease. Most CoA is newly diagnosed in&#xD;
      childhood; &lt; 25% recognized beyond 10 yrs.&#xD;
&#xD;
      CoA is mostly repaired in childhood by surgery or by balloon catheter dilation. Recurrence&#xD;
      rates range from 5-20%. Recurrence is often not recognized until adolescence. Balloon&#xD;
      expandable stents have become the predominant therapy in the USA and Europe for CoA treatment&#xD;
      in this age group. There are no FDA approved stents for this use. Biliary stents are&#xD;
      currently being used off label. Enrollment into a trial of bare metal Cheatham Platinum (CP)&#xD;
      Stents, designed for use in CoA, is completed. The Coarctation of the Aorta Stent Trial&#xD;
      (COAST) aims to confirm safety and efficacy of CP Stent for native and recurrent CoA.&#xD;
&#xD;
      There are CoA patients with clinical situations that place them at high risk of aortic wall&#xD;
      injury during bare metal stenting. Extreme narrowing, genetic aortic wall weakness and&#xD;
      advanced age are examples. Patients may present with aortic wall injury (aneurysm) related to&#xD;
      prior CoA repair. The occurrence after surgical repair is 3-4% and after balloon dilation&#xD;
      10-20%. Repair of these aneurysms is surgically challenging. The use of fabric-covered CP&#xD;
      Stents to prevent or repair aortic wall injury has become the treatment of choice in Europe&#xD;
      and recently in the US through the FDA Compassionate Use process. There are no alternative&#xD;
      devices available in the US. COAST II will test safety and efficacy of Covered CP Stents to&#xD;
      repair or prevent aortic wall injury associated with CoA.&#xD;
&#xD;
      Funding Source-FDA OOPD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are no prior trials of preventing or treating aortic injury associated with CoA and&#xD;
      thus no basis for comparison. A single outcome assessment will not suffice since patients can&#xD;
      receive a device for either indication. A 3-category Severity of Illness Scale (SIS) was&#xD;
      developed based on clinical judgment of a panel of pediatric cardiologists and reviewed by a&#xD;
      Data &amp; Safety Monitoring Board (DSMB) and the FDA Office of Device Evaluation. Five levels of&#xD;
      severity have been defined for each of the 3 illness categories, including: Upper extremity&#xD;
      hypertension, Upper to lower extremity pressure difference, and Severity of aortic wall&#xD;
      injury. The DSMB will assign a level of illness from the SIS for each patient at baseline and&#xD;
      one year follow up. Improvement by at least one level will indicate clinical importance.&#xD;
      Safety is evaluated by identifying adverse events and comparing their occurrence to surgical&#xD;
      repair of CoA in similar age groups reported in the medical literature.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study Participants With Grade 4 or 5 in Degree of Aortic Wall Injury (AWI) and/or Aortic Arch Obstruction Without Clinical Worsening</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Severity of Illness Scale (SIS) improvement increase of at least 1 grade from baseline to 12 month follow-up&#xD;
SIS is divided into 3 conditions &amp; 5 grades of severity: 1 = worst (reserved for AWI) , 5 = best) C1 Upper Extremity Systolic Blood Pressure (SBP) 2- &gt; 159 mmHg or any hpn on &gt;2 medications 3- 140-159 mmHg or elevated SBP on &gt;2 medications 4- 130-139 mmHg or normal SBP on &gt;2 medications 5- &lt;130 mmHg on 0-2 meds&#xD;
C2 Upper Extremity to Lower Extremity SBP difference 2- &gt;59 mmHg 3- 30-59 mmHg 4- 15-29 mmHg 5- &lt;15 mmHg&#xD;
C3&#xD;
Aortic Wall Injury severity levels:&#xD;
Uncontained rupture or large aneurysm&#xD;
Contained rupture or stable large aneurysm&#xD;
Small contained rupture or moderate aneurysm&#xD;
Acute, but stable AWI or small aneurysm&#xD;
No injury or minor aortic wall irregularity not in need of treatment.&#xD;
Grades for conditions represent comparable degrees of illness (0 worst, 5 best) -Grade 0 denotes death related to coarctation or study therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcomes - 1 Year</measure>
    <time_frame>1 years</time_frame>
    <description>Secondary Efficacy Outcomes&#xD;
At One Year: (A) Number of participants with arm-leg systolic blood pressure (SBP) differences &lt;15 mmHg and (B) Number of participants with normal or only mildly elevated SBP, no more than mild arm-leg SBP, no clinically significant residual aortic wall injury AND no worsening in any of these three categories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Outcomes - Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>Secondary Safety Outcomes&#xD;
The proportion of patients experiencing any serious or somewhat serious adverse event related to the stent or implant procedure by 24 months follow up, such as: new aortic wall injury within the region of covered CP Stent implantation, stent malposition, stent fracture, aortic wall aneurysms (early or late), or restenosis requiring reintervention, arterial access site injury, bleeding, etc.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Aortic Coarctation</condition>
  <arm_group>
    <arm_group_label>Treatment of Aortic Wall Injury</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Repair of aortic wall injury with covered CP Stents</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment of Aortic Wall Injury</intervention_name>
    <description>A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.</description>
    <arm_group_label>Treatment of Aortic Wall Injury</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Inclusion criteria for use of a Covered CP Stent:&#xD;
&#xD;
        Native or recurrent aortic coarctation*associated with ONE OR MORE of the following:&#xD;
&#xD;
          1. Acute or chronic aortic wall injury, or&#xD;
&#xD;
          2. Nearly atretic descending aorta to 3 mm or less in diameter, or&#xD;
&#xD;
          3. Genetic Syndromes associated with aortic wall weakening. Individuals with genetic&#xD;
             syndromes such as Marfan Syndrome, Turner's Syndrome or familial bicuspid aortic valve&#xD;
             and ascending aortic aneurysm, or&#xD;
&#xD;
          4. Advanced age. Men and woman aged 60 years or older.&#xD;
&#xD;
               -  The significance of aortic obstruction is left to the judgment of the&#xD;
                  participating investigator.&#xD;
&#xD;
        indications might include mild resting aortic obstruction associated with:&#xD;
&#xD;
        Exercise related upper extremity hypertension; Severe coarctation with multiple and/or&#xD;
        large arterial collaterals; Single ventricle physiology Left ventricular dysfunction&#xD;
        Ascending aortic aneurysm&#xD;
&#xD;
        + Aortic wall injury might include: Descending aortic aneurysm Descending aortic&#xD;
        pseudo-aneurysm Contained aortic wall rupture Non-contained rupture of the aortic wall&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient size too small for safe delivery of the device. The absolute lower limit for&#xD;
             inclusion under this protocol is 20 kg. However, serious femoral artery injury can&#xD;
             occur in small patients, particularly those in the 20-30 kg range and this risk must&#xD;
             be reviewed in detail with parents or guardians of children in this weight range.&#xD;
&#xD;
          2. Planned deployment diameter less than 10 mm or greater than 22 mm&#xD;
&#xD;
          3. Location requiring covered stent placement across a carotid artery*&#xD;
&#xD;
          4. Adults lacking capacity to consent&#xD;
&#xD;
          5. Pregnancy&#xD;
&#xD;
               -  crossing or covering of a subclavian artery is acceptable in certain situations,&#xD;
                  but only after alternative treatments have been considered.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Moore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rady Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John F Rhodes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nicklaus Children's Hospital f/k/a Miami Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa Bergersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julie A Vincent, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of New York-Presbyterian</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allison Cabalka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henri Justino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medecine, Texas Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Forbes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Rome, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joshua Kanter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phil Moore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Russel Hirsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacqueline Kreutzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Zellers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Medical Center Dallas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lourdes Prieto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory Fleming, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Healthcare of Atlanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Cheatham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory A Fleming, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rady Children's Hospital and Health Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of New York - Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital and Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine, Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center, Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>August 2, 2010</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <results_first_submitted>April 8, 2015</results_first_submitted>
  <results_first_submitted_qc>February 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 14, 2016</results_first_posted>
  <last_update_submitted>February 15, 2016</last_update_submitted>
  <last_update_submitted_qc>February 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Richard E. Ringel</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Coarctation</keyword>
  <keyword>Aorta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Coarctation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual patient data is confidential and not shared.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment of Aortic Wall Injury</title>
          <description>Repair of aortic wall injury with covered CP Stents&#xD;
Treatment of Aortic Wall Injury: A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment of Aortic Wall Injury</title>
          <description>Repair of aortic wall injury with covered CP Stents&#xD;
Treatment of Aortic Wall Injury: A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" lower_limit="6" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Study Participants With Grade 4 or 5 in Degree of Aortic Wall Injury (AWI) and/or Aortic Arch Obstruction Without Clinical Worsening</title>
        <description>Severity of Illness Scale (SIS) improvement increase of at least 1 grade from baseline to 12 month follow-up&#xD;
SIS is divided into 3 conditions &amp; 5 grades of severity: 1 = worst (reserved for AWI) , 5 = best) C1 Upper Extremity Systolic Blood Pressure (SBP) 2- &gt; 159 mmHg or any hpn on &gt;2 medications 3- 140-159 mmHg or elevated SBP on &gt;2 medications 4- 130-139 mmHg or normal SBP on &gt;2 medications 5- &lt;130 mmHg on 0-2 meds&#xD;
C2 Upper Extremity to Lower Extremity SBP difference 2- &gt;59 mmHg 3- 30-59 mmHg 4- 15-29 mmHg 5- &lt;15 mmHg&#xD;
C3&#xD;
Aortic Wall Injury severity levels:&#xD;
Uncontained rupture or large aneurysm&#xD;
Contained rupture or stable large aneurysm&#xD;
Small contained rupture or moderate aneurysm&#xD;
Acute, but stable AWI or small aneurysm&#xD;
No injury or minor aortic wall irregularity not in need of treatment.&#xD;
Grades for conditions represent comparable degrees of illness (0 worst, 5 best) -Grade 0 denotes death related to coarctation or study therapy</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Participants available for analysis at one year</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment of Aortic Wall Injury</title>
            <description>Repair of aortic wall injury with covered CP Stents&#xD;
Treatment of Aortic Wall Injury: A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Participants With Grade 4 or 5 in Degree of Aortic Wall Injury (AWI) and/or Aortic Arch Obstruction Without Clinical Worsening</title>
          <description>Severity of Illness Scale (SIS) improvement increase of at least 1 grade from baseline to 12 month follow-up&#xD;
SIS is divided into 3 conditions &amp; 5 grades of severity: 1 = worst (reserved for AWI) , 5 = best) C1 Upper Extremity Systolic Blood Pressure (SBP) 2- &gt; 159 mmHg or any hpn on &gt;2 medications 3- 140-159 mmHg or elevated SBP on &gt;2 medications 4- 130-139 mmHg or normal SBP on &gt;2 medications 5- &lt;130 mmHg on 0-2 meds&#xD;
C2 Upper Extremity to Lower Extremity SBP difference 2- &gt;59 mmHg 3- 30-59 mmHg 4- 15-29 mmHg 5- &lt;15 mmHg&#xD;
C3&#xD;
Aortic Wall Injury severity levels:&#xD;
Uncontained rupture or large aneurysm&#xD;
Contained rupture or stable large aneurysm&#xD;
Small contained rupture or moderate aneurysm&#xD;
Acute, but stable AWI or small aneurysm&#xD;
No injury or minor aortic wall irregularity not in need of treatment.&#xD;
Grades for conditions represent comparable degrees of illness (0 worst, 5 best) -Grade 0 denotes death related to coarctation or study therapy</description>
          <population>Participants available for analysis at one year</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Efficacy Outcomes - 1 Year</title>
        <description>Secondary Efficacy Outcomes&#xD;
At One Year: (A) Number of participants with arm-leg systolic blood pressure (SBP) differences &lt;15 mmHg and (B) Number of participants with normal or only mildly elevated SBP, no more than mild arm-leg SBP, no clinically significant residual aortic wall injury AND no worsening in any of these three categories</description>
        <time_frame>1 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment of Aortic Wall Injury</title>
            <description>Repair of aortic wall injury with covered CP Stents&#xD;
Treatment of Aortic Wall Injury: A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Efficacy Outcomes - 1 Year</title>
          <description>Secondary Efficacy Outcomes&#xD;
At One Year: (A) Number of participants with arm-leg systolic blood pressure (SBP) differences &lt;15 mmHg and (B) Number of participants with normal or only mildly elevated SBP, no more than mild arm-leg SBP, no clinically significant residual aortic wall injury AND no worsening in any of these three categories</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>(A) arm-leg SBP difference &lt;15 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>(B) Good clinical status at 1 yr w/o worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Safety Outcomes - Adverse Events</title>
        <description>Secondary Safety Outcomes&#xD;
The proportion of patients experiencing any serious or somewhat serious adverse event related to the stent or implant procedure by 24 months follow up, such as: new aortic wall injury within the region of covered CP Stent implantation, stent malposition, stent fracture, aortic wall aneurysms (early or late), or restenosis requiring reintervention, arterial access site injury, bleeding, etc.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment of Aortic Wall Injury</title>
            <description>Repair of aortic wall injury with covered CP Stents&#xD;
Treatment of Aortic Wall Injury: A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Safety Outcomes - Adverse Events</title>
          <description>Secondary Safety Outcomes&#xD;
The proportion of patients experiencing any serious or somewhat serious adverse event related to the stent or implant procedure by 24 months follow up, such as: new aortic wall injury within the region of covered CP Stent implantation, stent malposition, stent fracture, aortic wall aneurysms (early or late), or restenosis requiring reintervention, arterial access site injury, bleeding, etc.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment of Aortic Wall Injury</title>
          <description>Repair of aortic wall injury with covered CP Stents&#xD;
Treatment of Aortic Wall Injury: A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Wall Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising or Hemorrhage</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Wall Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Aortic Wall Injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Device Specific</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Non-Classified</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain or Discomfort</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Richard E. Ringel</name_or_title>
      <organization>Johns Hopkins Hospital</organization>
      <phone>410-614-6745</phone>
      <email>rringel@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

